CN105814041B - 用作tnf活性调节剂的苯并三唑衍生物 - Google Patents

用作tnf活性调节剂的苯并三唑衍生物 Download PDF

Info

Publication number
CN105814041B
CN105814041B CN201480067048.2A CN201480067048A CN105814041B CN 105814041 B CN105814041 B CN 105814041B CN 201480067048 A CN201480067048 A CN 201480067048A CN 105814041 B CN105814041 B CN 105814041B
Authority
CN
China
Prior art keywords
base
alkyl
methyl
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480067048.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105814041A (zh
Inventor
D·C·布鲁金斯
B·克罗普里恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CN105814041A publication Critical patent/CN105814041A/zh
Application granted granted Critical
Publication of CN105814041B publication Critical patent/CN105814041B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201480067048.2A 2013-12-09 2014-12-08 用作tnf活性调节剂的苯并三唑衍生物 Expired - Fee Related CN105814041B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1321740.1A GB201321740D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
GB1321740.1 2013-12-09
PCT/EP2014/076847 WO2015086508A1 (en) 2013-12-09 2014-12-08 Benzotriazole derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
CN105814041A CN105814041A (zh) 2016-07-27
CN105814041B true CN105814041B (zh) 2018-12-18

Family

ID=50000423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480067048.2A Expired - Fee Related CN105814041B (zh) 2013-12-09 2014-12-08 用作tnf活性调节剂的苯并三唑衍生物

Country Status (10)

Country Link
US (1) US9957255B2 (https=)
EP (1) EP3080107B1 (https=)
JP (1) JP6483701B2 (https=)
CN (1) CN105814041B (https=)
BR (1) BR112016011788B1 (https=)
CA (1) CA2931584C (https=)
ES (1) ES2775535T3 (https=)
GB (1) GB201321740D0 (https=)
RU (1) RU2677696C1 (https=)
WO (1) WO2015086508A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN109988093B (zh) * 2017-12-29 2023-04-07 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CA3114166A1 (en) 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
MX2021003559A (es) 2018-09-28 2021-08-24 Acucela Inc Inhibidores de vap-1.
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
KR20250005348A (ko) 2022-04-26 2025-01-09 프락시스 프리시젼 메디신즈, 인크. 신경 장애의 치료

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426225A2 (en) * 1989-11-01 1991-05-08 Janssen Pharmaceutica N.V. (6,7-dihydro-5H-pyrrolo[1,2-c]-imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
US5496954A (en) * 1995-02-10 1996-03-05 American Cyanamid Co. 6-heterocyclyl-1-(substituted phenyl)benzotriazole herbicidal agents
WO2002006219A2 (en) * 2000-07-15 2002-01-24 Basf Aktiengesellschaft 1-alkyl-3-[1-(substituted phenyl) benzotriazol-6-yl] uracils
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
CN101553224A (zh) * 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
CN102123710A (zh) * 2008-08-14 2011-07-13 默克专利有限公司 用于治疗肿瘤的二环三唑衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3129447A1 (de) * 1981-07-25 1983-02-10 Dr. Karl Thomae Gmbh, 7950 Biberach "neue benztriazole, ihre herstellung und ihre verwendung als arzneimittel"
US5369086A (en) * 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
RU2183628C1 (ru) * 2001-06-22 2002-06-20 Ярославский государственный технический университет Гетероциклические о-дикарбонитрилы
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
EP1893588A1 (en) * 2005-06-10 2008-03-05 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
US7635915B2 (en) * 2006-04-26 2009-12-22 Cree Hong Kong Limited Apparatus and method for use in mounting electronic elements
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
WO2010141360A1 (en) * 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
WO2013051672A1 (ja) * 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
DK2785710T3 (en) * 2011-12-01 2017-12-04 Chemocentryx Inc SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426225A2 (en) * 1989-11-01 1991-05-08 Janssen Pharmaceutica N.V. (6,7-dihydro-5H-pyrrolo[1,2-c]-imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
US5496954A (en) * 1995-02-10 1996-03-05 American Cyanamid Co. 6-heterocyclyl-1-(substituted phenyl)benzotriazole herbicidal agents
US5523277A (en) * 1995-02-10 1996-06-04 American Cyanamid Company 6-heterocyclyl-1-(substituted phenyl)benzotriazole herbicidal agents
WO2002006219A2 (en) * 2000-07-15 2002-01-24 Basf Aktiengesellschaft 1-alkyl-3-[1-(substituted phenyl) benzotriazol-6-yl] uracils
CN101553224A (zh) * 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
CN102123710A (zh) * 2008-08-14 2011-07-13 默克专利有限公司 用于治疗肿瘤的二环三唑衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Organocatalytic Triazole Formation, Followed by Oxidative Aromatization: Regioselective Metal-Free Synthesis of Benzotriazoles.;Dhevalapally B. Ramachary, et al.,;《 Chem. Eur. J.》;20130812;第19卷;第13175-13181页. *

Also Published As

Publication number Publication date
CA2931584A1 (en) 2015-06-18
JP6483701B2 (ja) 2019-03-13
US9957255B2 (en) 2018-05-01
BR112016011788A2 (https=) 2017-08-08
WO2015086508A1 (en) 2015-06-18
EP3080107B1 (en) 2020-01-22
ES2775535T3 (es) 2020-07-27
EP3080107A1 (en) 2016-10-19
CA2931584C (en) 2021-11-23
RU2677696C1 (ru) 2019-01-21
CN105814041A (zh) 2016-07-27
GB201321740D0 (en) 2014-01-22
RU2016127623A (ru) 2018-01-23
JP2017502936A (ja) 2017-01-26
US20160297799A1 (en) 2016-10-13
BR112016011788B1 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
CN105814041B (zh) 用作tnf活性调节剂的苯并三唑衍生物
CN105814025B (zh) 用作tnf活性调节剂的四氢苯并咪唑衍生物
CN105814043B (zh) 用作tnf活性调节剂的三唑并吡啶衍生物
CN112135824B (zh) 作为免疫调节剂的杂环化合物
JP7554672B2 (ja) Ｉｒａｋ分解剤およびそれらの使用
CN105814052B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN104470924B (zh) 作为tnf活性调节剂的咪唑并吡嗪衍生物
CN102971317B (zh) 四氢-吡啶并-嘧啶衍生物
CN105814022B (zh) 作为tnf活性调节剂的稠合的二环杂芳族衍生物
CN105814061B (zh) 作为tnf活性调节剂的咪唑并哒嗪衍生物
CN104428293B (zh) 调节TNFα的苯并咪唑类
CN105814045B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814051B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN105814060B (zh) 用作tnf活性调节剂的咪唑并三嗪衍生物
CN105814059B (zh) 作为tnf活性调节剂的咪唑并嘧啶衍生物
CN109195969A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
KR20220145325A (ko) Irak 분해제 및 이의 용도
EP3833439B1 (en) Benzimidazole inhibitors of pad enzymes
KR20160135283A (ko) 5-치환된 인다졸-3-카르복스아미드 및 이의 제조 및 용도
BR112020015328A2 (pt) Inibidores de gcn2 e usos dos mesmos
CN109219609A (zh) 作为tnf活性调节剂的稠合六环咪唑衍生物
TW201016676A (en) Heterocyclic derivatives and methods of use thereof
CA3192393A1 (en) Piperidinyl small molecule degraders of helios and methods of use
TW200813039A (en) 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
CN105814065B (zh) 用作tnf活性调节剂的咪唑并噻唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Brussels

Patentee after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Patentee before: UCB BIOPHARMA SPRL

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181218